


# ITW/



92399.1

PATENT

DOCKET 13510 CIP

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant: LEAKE *et al.* Examiner: BOWMAN, Amy Hudson  
Serial No.: 10/613,077 Group Art Unit: 1635  
Filed: July 01, 2003  
For: Stabilized Polynucleotides for Use in RNA Interference  
Customer No.: 23719 Kalow & Springut LLP  
488 Madison Avenue, 19th Floor  
New York, New York 10022

June 21, 2005

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents:

In accordance with 37 C.F.R. §§ 1.56 and 1.97 through 1.98, Applicants wish to make known to the Patent and Trademark Office the references set forth on the attached form PTO/SB/08A and B. Applicants do not admit that the references are “prior art” under 35 U.S.C. §§ 102 or 103, and specifically reserve the right to traverse or antedate any such reference. Although the aforesaid references are made known to the Patent and Trademark Office in compliance with Applicants’ duty to disclose all information of which they are aware and believe relevant to the examination of the above-identified application, Applicants believe that their invention is patentable.


**Certificate of Mailing Under 37 C.F.R. 1.8**

I hereby certify that this correspondence is being deposited on the date shown below with the United States Postal Service as first class mail with sufficient postage in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

JR Smelann  
(Signature)


TOR SMELANN  
(Printed Name of Person Signing Certificate)

21 JUNE 2005  
(Date)



### I. PATENT APPLICATION PUBLICATIONS

Patent Application Publication No.	Publication Date	Title
US 2004/0014956 A1 by Woolf, <i>et al.</i>	January 22, 2004	Double-stranded oligonucleotides
US 2004/0054155 A1 by Woolf, <i>et al.</i>	March 18, 2004	Oligonucleotide compositions with enhanced efficiency
US 2004/0096880 A1 by Kmiec, <i>et al.</i>	May 20, 2004	Compositions and methods for the treatment of diseases exhibiting protein misassembly and aggregation
US 2004/0147022 A1 by Baker, <i>et al.</i>	July 29, 2004	2'-methoxy substituted oligomeric and compositions for use in gene modulations
US 2004/0147023 A1 by Baker, <i>et al.</i>	July 29, 2004	Chimeric oligomeric compounds and their use in gene modulation
US 2004/0248299 A1 by Jayasena, <i>et al.</i>	December 09, 2004	RNA interference
US 2005/0020521 A1 by Rana, <i>et al.</i>	January 27, 2005	In vivo gene silencing by chemically modified and stable siRNA
US 2005/0020525 A1 by McSwiggen, <i>et al.</i>	January 27, 2005	RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
US 2005/0026160 A1 by Allerson, <i>et al.</i>	February 03, 2005	Compositions comprising alternating 2'-modified nucleosides for use in gene modulation
US 2005/0130181 A1 by McSwiggen	June 16, 2005	RNA interference mediated inhibition of wingless gene expression using short interfering nucleic acid (siNA)



## II. FOREIGN PATENT DOCUMENTS

Publication No.	Country	Publication Date
EP 1 389 637 A1	EPO	18 February 2004
WO 03/064625 A2	WIPO	07 August 2003
WO 03/064625 A3	WIPO	07 August 2003
WO 03/064626 A2	WIPO	07 August 2003
WO 2003/064626 A3	WIPO	07 August 2003
WO 03/070193 A2	WIPO	28 August 2003
WO 03/070918 A2	WIPO	28 August 2003
WO 2005/019453 A2	WIPO	03 March 2005

## III. NON PATENT PUBLICATIONS

CHIU, *et al.* (2003) siRNA function in RNAi: A chemical modification analysis, *RNA* 9/9:1034-1048.

CZAUDERNA *et al.* (2003) Structural variations and stabilizing modifications of synthetic siRNAs in mammalian cells, *Nucleic Acids Res.* 31/11:2705-2716.

HOLEN *et al.* (2003) Similar behaviour of single-strand and double-strand siRNAs suggests they act through a common RNAi pathway, *Nucleic Acids Res.* 31/9:2401-2407.


LIANG, L. *et al.* (2002) Optimizing the delivery systems of chimeric RNA-DNA oligonucleotides: Beyond general oligonucleotide transfer, *Eur. J. Biochem* 269:5753-5758.

MONIA, *et al.* (1993) Evaluation of 2'-Modified Oligonucleotides Containing 2'-Deoxy Gaps as Antisense Inhibitors of Gene Expression, *J. Biol. Chem.* 268/19:14514-14522.

Applicant LEAKE *et al*  
Serial No.: 10/613,077  
Filed: July 01, 2003  
Information Disclosure Statement  
June 21, 2005  
Page 4 of 4

Applicant encloses a check in the amount of \$180.00 for the filing of this information disclosure statement. If any additional fees are deemed due or any overpayment has been made please charge, or credit our deposit Account No. 11-0171 for such sum.

Respectfully submitted,

A handwritten signature in black ink, appearing to read 'Tor Smeland', is written over a horizontal line.

Tor Smeland  
Registration No.: 43,131  
Attorney for Applicant

Kalow & Springut LLP  
(212) 813-1600



PTO/SB/08A (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

**Complete if Known**

Application Number	10/613,077
Filing Date	July 01, 2003
First Named Inventor	LEAKE, et al.
Art Unit	1635
Examiner Name	BOWMAN, Amy Hudson
Attorney Docket Number	13510 CIP

Sheet 1 of 3

**U. S. PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			
		US- 2004/0014956 A1	01-22-2004	Woolf, et al.	
		US- 2004/0054155 A1	03-18-2004	Woolf, et al.	
		US- 2004/0096880 A1	05-20-2004	Kniec, et al.	
		US- 2004/0147022 A1	07-29-2004	Baker, et al.	
		US- 2004/0147023 A1	07-29-2004	Baker, et al.	
		US- 2004/0248299 A1	12-09-2004	Jayasena, et al.	
		US- 2005/0020521 A1	01-27-2005	Rana, et al.	
		US- 2005/0020525 A1	01-27-2005	McSwiggen, et al.	
		US- 2005/0026160 A1	02-03-2005	Allerson, et al.	
		US- 2005/0130181 A1	06-16-2005	McSwiggen	
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)				
		EP 1 389 637 A1	02-18-2004	atugen AG		
		WO 03/064625 A2	08-07-2003	Sequitur, Inc.		
		WO 03/064625 A3	08-07-2003	Sequitur, Inc.		
		WO 03/064626 A2	08-07-2003	Sequitur, Inc.		
		WO 03/064626 A3	08-07-2003	Sequitur, Inc.		
		WO 03/070193 A2	08-28-2003	Sirna Therapeutics, Inc.		

Examiner  
SignatureDate  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

**(Use as many sheets as necessary)**

**Complete if Known**

Application Number	10/613,077
Filing Date	July 01, 2003
First Named Inventor	<b>LEAKE, et al.</b>
Art Unit	1635
Examiner Name	BOWMAN, Amy Hudson
Attorney Docket Number	13510 CIP

Sheet	2	of	3
-------	---	----	---

## U. S. PATENT DOCUMENTS

[illegible]

## FOREIGN PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> *Number <sup>4</sup> *Kind Code <sup>5</sup> (if known)				
		WO 03/070918 A2	08-28-2003	Ribozyme Pharmaceuticals		
		WO 2005/019453 A2	03-03-2005	Sirna Pharmaceuticals		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

**If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.**

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

**Complete if Known**

Sheet	3	of	3	Application Number	10/613,077
				Filing Date	July 01, 2003
				First Named Inventor	LEAKE, et al.
				Art Unit	1635
				Examiner Name	BOWMAN, Amy Hudson
				Attorney Docket Number	13510 CIP

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		CHIU, et al. (2003) siRNA function in RNAi: A chemical modification analysis, RNA 9/9:1034-1048	
		CZAUDERNA, et al. (2003) Structural variations and stabilizing modifications of synthetic siRNAs in mammalian cells, Nucleic Acids Res. 31/11:2705-2716.	
		HOLEN, et al. (2003) Similiar behaviour of single-stranded and double-stranded siRNAs suggests they act through a common RNAi pathway, Nucleic Acids Res. 31/9:2401-2407.	
		LIANG, L. et al. (2002) Optimizing the delivery system of chimeric RNA-DNA oligonucleotides: Beyond general oligonucleotide transfer, Eur. J. Biochen 269:5753-5758.	
		MONIA, et al. (1993) Evaluation of 2'-Modified Oligonucleotides Containing 2'-Deoxy Gaps as Antisense Inhibitors of Gene Expression, J. Biol. Chem. 268/19:14514-14522.	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.